A CAR specific for both HER2 and MUC1 for breast cancer showed that dual targeting can lead to the delivery of complementary signals that enhance T-cell proliferation [48], and dual-target CARs specific for HER2 and IL13Rα2 mitigate antigen escape in a xenograft glioma model [49]. Here, ERBB2 is linked to breast carcinoma.